Immunoglobulins response of COVID-19 patients, COVID-19 vaccine recipients, and random individuals

Background The development of specific immunoglobulins to COVID-19 after natural infection or vaccination has been proposed. The efficacy and dynamics of this response are not clear yet. Aim This study aims to analyze the immunoglobulins response among COVID-19 patients, COVID-19 vaccine recipients and random individuals. Methods A total of 665 participants including 233 COVID-19 patients, 288 COVID-19 vaccine recipients, and 144 random individuals were investigated for anti-COVID-19 immunoglobulins (IgA, IgG, IgM). Results Among COVID-19 patients, 22.7% had detectable IgA antibodies with a mean of 27.3 +/- 57.1 ng/ml, 29.6% had IgM antibodies with a mean of 188.4 +/- 666.0 BAU/ml, while 59.2% had IgG antibodies with a mean of 101.7 +/- 139.7 BAU/ml. Pfizer-BioNTech vaccine recipients had positive IgG in 99.3% with a mean of 515.5 +/- 1143.5 BAU/ml while 85.7% of Sinopharm vaccine recipients had positive IgG with a mean of 170.0 +/- 230.0 BAU/ml. Regarding random individuals, 54.9% had positive IgG with a mean of 164.3 +/- 214 BAU/ml. The peak IgM response in COVID-19 patients was detected early at 15-22 days, followed by IgG peak at 16-30 days, and IgA peak at 0-60 days. IgM antibodies disappeared at 61-90 days, while IgG and IgA antibodies decreased slowly after the peak and remained detectable up to 300 days. The frequency of IgG positivity among patients was significantly affected by increased age, admission department (inpatient or outpatient), symptoms, need for oxygen therapy, and increased duration between positive COVID-19 RT PCR test and serum sampling (p<0.05). Positive correlations were noted between different types of immunoglobulins (IgG, IgM, and IgA) among patients. Conclusions Natural infection and COIVD-19 vaccines provide IgG-mediated immunity. The class, positivity, mean, efficacy, and duration of immunoglobulins response are affected by the mechanism of immunity and host related variables. Random community individuals had detectable COVID-19 IgG at similar to 55%, far from reaching herd immunity levels.